» Articles » PMID: 26087772

High Neutrophil-to-lymphocyte Ratio Predicts Poor Clinical Outcome in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel Chemotherapy

Overview
Journal Int J Urol
Specialty Urology
Date 2015 Jun 20
PMID 26087772
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio in patients receiving chemotherapy with docetaxel for castration-resistant prostate cancer.

Methods: A total of 57 castration-resistant prostate cancer patients treated between 2009 and 2014 were included in the present retrospective study. All patient data, including clinicopathological factors, were assessed. Univariate and multivariate Cox regression models were used to predict overall survival and progression-free survival after chemotherapy initiation.

Results: The median overall survival and progression-free survival were determined as 19.0 months (range 1-61 months) and 10.0 months (range 1-56 months), respectively. The cut-off level of the neutrophil-to-lymphocyte ratio was set as the median value of 3.5 among all patients in this study. In Kaplan-Meier analysis, the median overall survival and progression-free survival were shorter in patients with a high neutrophil-to-lymphocyte ratio compared with those with a low neutrophil-to-lymphocyte ratio (15 vs 20 months, P = 0.0125; and 9.5 vs 15 months, P = 0.0132, respectively). The overall survival and progression-free survival periods in patients with a high neutrophil-to-lymphocyte ratio were significantly shorter than those of patients with a low neutrophil-to-lymphocyte ratio (P = 0.0178 and 0.0176, respectively). In the multivariate analysis, a high neutrophil-to-lymphocyte ratio was an independent predictor of overall survival and progression-free survival (hazard ratio 2.728, 95% confidence interval 1.05-7.09, P = 0.039; and hazard ratio 2.376, 95% confidence interval 1.12-5.06, P=0.024, respectively).

Conclusion: The present study results suggest that the neutrophil-to-lymphocyte ratio is a useful prognostic factor in patients with castration-resistant prostate cancer treated by docetaxel chemotherapy. These findings might be useful in determining treatment strategies in the future.

Citing Articles

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis.

Zhang Y, Zhou X, Xu R, Luo G, Wang X BMC Urol. 2025; 25(1):17.

PMID: 39865253 PMC: 11770999. DOI: 10.1186/s12894-024-01685-4.


Inflammation-related indicators have a potential to increase overall quality of the prostate cancer management: a narrative review.

Zhou M, Liang J, Hui J, Xu J Transl Androl Urol. 2023; 12(5):809-822.

PMID: 37305618 PMC: 10251092. DOI: 10.21037/tau-23-55.


Pretreatment neutrophil-to-lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration-sensitive prostate cancer.

Salah S, Abu-Hijlih R, Abuhijla F, Tamimi F, Al-Tell A, Shahait M Cancer Rep (Hoboken). 2021; 4(5):e1392.

PMID: 34159754 PMC: 8551990. DOI: 10.1002/cnr2.1392.


Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review.

Chen W, Kong D, Li L Asian J Androl. 2020; 23(2):163-169.

PMID: 33159024 PMC: 7991808. DOI: 10.4103/aja.aja_53_20.


Treatment Stratification of Patients with Metastatic Castration-Resistant Prostate Cancer by Machine Learning.

Deng K, Li H, Guan Y iScience. 2020; 23(2):100804.

PMID: 31978751 PMC: 6976944. DOI: 10.1016/j.isci.2019.100804.